non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified Nonalcoholic fatty liver disease (NAFLD)
Conditions
Interventions
Intervention 1: intervention group : Livergol tablet containing silymarin(Goldaru Company, Iran) were administered for 12 weeks with dosage of 5 mg per kg body weight divided in three dose with me
Treatment - Drugs
Lifestyle
intervention group : Livergol tablet containing silymarin(Goldaru Company, Iran) were administered for 12 weeks with dosage of 5 mg per kg body weight divided in three dose with meal. Patients are
Control group: life style change including increase in physical activity and decease ingestion of fatty and high calori diets.
Sponsors
Vice Chancellor for Research of Shahrekord University of Medical Science
Eligibility
Sex/Gender
All
Age
5 Years to 16 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria : Obese or overweight child and adolescent with sonographic finding of fatty liver Exclusion criteria: Age less than 5 and more than 16 years old; patients with metabolic syndromes; viral hepatitis; wilson disease; auto immune hepatitis; juvenile hemochromatosis and other underlying diseases; allergy or intolerance to medication
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grading of fatty liver in sonography. Timepoint: At arrival to study and 12 weeks later. Method of measurement: Sonographic grading. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver enzymes, transaminases. Timepoint: At arrival and after 12 weeks. Method of measurement: Serum. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Fatemeh Famouri
Isfahan University of Medical Science
Outcome results
None listed